pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

183 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 213 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: drug expiry×type: filing×type: phase 2 completion×clear all
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa213
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Oncology37
    • Infectious Disease13
    • Immunology11
    • Women's Health10
    • Cardiology10
    • Ophthalmology9
    • Pulmonology7
    • Dermatology7
    • Pain4

    Week of Apr 20, 2026

    36
    ›Apr 24, 2026drug expiry90d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry90d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoUniversity Health Network — bevacizumab (Phase II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoXijing Hospital — propofol (Phase II Trial Completion)PROPOFOL

    Therapy area: Central Nervous System. Indication: Delirium

    full page →PROPOFOL →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoKothiwal Dental College and Research Centre — platelet rich plasma (Phase II Trial Completion)platelet rich plasma

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →platelet rich plasma →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

    Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

    full page →lixudebart →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoSwinburne University of Technology — dronabinol (Phase II Trial Completion)dronabinol

    Therapy area: Central Nervous System. Indication: Anxiety Disorders, Insomnia, Pain

    full page →dronabinol →source: globaldata
    ›Apr 24, 2026phase 2 completion90d agoJapanese Governmental Office — capecitabine (Phase II Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoAssiut University — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Other Diseases. Indication: Other Disease

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)Efudex

    Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)

    full page →Efudex →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoHai Phong Medical University — Biolizin (Phase II Trial Completion)Biolizin

    Therapy area: Central Nervous System. Indication: Appetite (Eating) Disorders

    full page →Biolizin →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoKaraman Training and Research Hospital — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Osteoarthritis, Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoChina Agricultural University — green tea (Phase II Trial Completion)green tea

    Therapy area: Metabolic Disorders. Indication: Obesity

    full page →green tea →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoMR Healthcare Pvt Ltd — Dyberine (Phase II Trial Completion)Dyberine

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →Dyberine →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTehran University of Medical Sciences — FOLFOX [leucovorin + fluorouracil + oxaliplatin] (Phase II Trial Completion)FOLFOX [leucovorin + fluorouracil + oxaliplatin]

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →FOLFOX [leucovorin + fluorouracil + oxaliplatin] →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoNational Institute of Siddha — undisclosed siddha medicine (Phase II Trial Completion)undisclosed siddha medicine

    Therapy area: Respiratory. Indication: Asthma

    full page →undisclosed siddha medicine →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoJawaharlal Nehru Medical College Ajmer — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →blinatumomab →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoNizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Post-Operative Pain, Renal Stones/Calculi

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

    full page →Himani fast relief gel →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoJawaharlal Nehru Medical College — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Other Diseases. Indication: Injury, Post-Operative Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoSeoul National University — onabotulinumtoxin A (Phase II Trial Completion)onabotulinumtoxin A

    Therapy area: Central Nervous System. Indication: Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy)

    full page →onabotulinumtoxin A →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoNational Taiwan University Hospital — levocarnitine (Phase II Trial Completion)Carnitor

    Therapy area: Gastrointestinal. Indication: Unspecified Gastrointestinal Disorders

    full page →Carnitor →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoFuzhou Second General Hospital — butorphanol (Phase II Trial Completion)butorphanol

    Therapy area: Musculoskeletal Disorders. Indication: Unspecified Musculoskeletal Disorders

    full page →butorphanol →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →unani medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoBanaras Hindu University — oxytocin (Phase II Trial Completion)Oxytocin Hikma

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →Oxytocin Hikma →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoAnyang Tumor Hospital — camrelizumab (Phase II Trial Completion)apatinib mesylate

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →apatinib mesylate →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoChongqing Jinsaixing Medical Technology Co Ltd — Neauvia Intense (Phase II Trial Completion)Neauvia Intense

    Therapy area: Dermatology. Indication: Wrinkles

    full page →Neauvia Intense →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoAll India Institute of Medical Sciences Bibinagar — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post-Operative Pain, Umbilical Hernia

    full page →dexmedetomidine →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoClostraBio Inc — CLB-101 (Phase II Trial Completion)CLB-101

    Therapy area: Gastrointestinal, Metabolic Disorders. Indication: Obesity, Overweight, Unspecified Gastrointestinal Disorders

    full page →CLB-101 →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoWinSanTor Inc — pirenzepine (Phase II Trial Completion)pirenzepine

    Therapy area: Toxicology. Indication: Chemotherapy Induced Peripheral Neuropathy

    full page →pirenzepine →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoMemorial Sloan Kettering Cancer Center — iberdomide hydrochloride (Phase II Trial Completion)iberdomide hydrochloride

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease)

    full page →iberdomide hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoBharati Vidyapeeth Deemed University — cinnamon (Phase II Trial Completion)cinnamon

    Therapy area: Metabolic Disorders. Indication: Glucose Intolerance

    full page →cinnamon →source: globaldata

    Week of Apr 27, 2026

    14
    ›Apr 27, 2026phase 2 completion87d agoSustained Therapeutics Inc — lidocaine SR (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 27, 2026phase 2 completion
    ← prev
    page 1 of 4
    next →
    87d ago
    SMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoChacha Nehru Bal Chikitsalaya — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoOrthomedico Inc — lactococcus lactis subsp. cremoris YRC3780 (Phase II Trial Completion)lactococcus lactis subsp. cremoris YRC3780

    Therapy area: Central Nervous System. Indication: Sleep Disorders

    full page →lactococcus lactis subsp. cremoris YRC3780 →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

    full page →nivolumab →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoChina Red Cross Foundation — sufentanil (Phase II Trial Completion)sufentanil

    Therapy area: Gastrointestinal, Genito Urinary System. Indication: Hernia, Urinary Retention

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoKonya City Hospital — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post-Operative Pain, Postoperative Ileus

    full page →fentanyl ER →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoBC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Appendicitis, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 28, 2026drug expiry86d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry86d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry86d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026phase 2 completion86d agoChangzhou Hengbang Pharmaceutical Co Ltd — HS-10374 (Phase II Trial Completion)HS-10374

    Therapy area: Musculoskeletal Disorders. Indication: Psoriatic Arthritis

    full page →HS-10374 →source: globaldata
    ›Apr 28, 2026phase 2 completion86d agoKS Hegde Medical Academy — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Hormonal Disorders. Indication: Endocrine Gland Disorders

    full page →fentanyl ER →source: globaldata
    $GSK50.78+1.48%